ZBIO
Zenas BioPharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Zenas BioPharma, Inc.
27.79
−0.60 · −2.13%
post 27.79 0.00%
No thesis.
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $241.3M | 16.06% | +4.68% | |
| 2 | SR One Capital ManagementSR One | $127.9M | 8.51% | 0.00% | |
| 3 | NEA ManagementNEA | $102.1M | 6.80% | 0.00% | |
| 4 | Enavate Sciences GPEnavate Sciences GP | $99.5M | 6.62% | 0.00% | |
| 5 | Federated InvestorsFederated Investors | $79.1M | 5.27% | −0.33% | |
| 6 | BlackRockBlackRockindex-like | $68.2M | 4.54% | +31.84% | |
| 7 | Capital International InvestorsCapital International Investors | $63.5M | 4.23% | +2.83% | |
| 8 | Polar Capital HoldingsPolar Capital | $61.2M | 4.08% | −5.32% | |
| 9 | Fairmount Funds ManagementFairmount Funds | $59.9M | 3.99% | 0.00% | |
| 10 | State StreetState Streetindex-like | $52.2M | 3.47% | +39.71% | |
| 11 | NVP AssociatesNVP | $46.7M | 3.11% | 0.00% | |
| 12 | Wellington Management GroupWellington | $40.5M | 2.69% | +27.91% | |
| 13 | Vanguard Capital ManagementVanguardindex-like | $34.4M | 2.29% | +8.79% | |
| 14 | Bank of AmericaBank of America | $31.2M | 2.08% | +217.03% | |
| 15 | T. Rowe Price AssociatesT. Rowe Price | $31.1M | 2.07% | +243.42% | |
| 16 | AlliancebernsteinAlliancebernstein | $28.0M | 1.86% | +22.96% | |
| 17 | Geode Capital ManagementGeodeindex-like | $22.4M | 1.49% | +34.60% | |
| 18 | Two Sigma InvestmentsTwo Sigma | $20.7M | 1.38% | +196.36% | |
| 19 | EcoR1 CapitalEcoR1 Capital | $20.0M | 1.33% | 0.00% | |
| 20 | Millennium ManagementMillennium | $16.8M | 1.12% | +38.52% | |
| 21 | Woodline PartnersWoodline Partners | $15.0M | 1.00% | 0.00% | |
| 22 | Balyasny Asset ManagementBalyasny | $14.6M | 0.97% | −13.54% | |
| 23 | Arrowpoint Asset ManagementArrowpoint | $14.6M | 0.97% | −12.99% | |
| 24 | Silverarc Capital ManagementSilverarc | $12.9M | 0.86% | −55.12% | |
| 25 | Rock Springs Capital ManagementRock Springs | $12.7M | 0.85% | 0.00% |
145 managers report $1.5B of Zenas BioPharma on form 13F for the quarter ended Jun 30 '26. 18 of them hold 80% of it; FMR is largest at 16.06%.
Linked news
No implied move.
No implied move.
Expected move
No implied move.